IL2 and plasma cell myeloma: We compared the outcome of the patients included in the DLI-NK trial to a historical control cohort of patients treated in the same center who did not receive IL-2 NK (n = 61), including 27 AML, 16 lymphoma, 12 myeloma, 5 ALL, and 1 CLL.